Development and validation of a risk assessment scale for infusion port occlusion in malignant tumor patients
10.3760/cma.j.cn115682-20240220-00847
- VernacularTitle:恶性肿瘤患者输液港堵塞风险评估量表的编制及信效度检验
- Author:
Xujing CUI
1
;
Yuling LI
;
Xiaohong MENG
;
Xiaoya HOU
;
Jing YU
Author Information
1. 山西医科大学护理学院，太原 030001
- Keywords:
Malignant neoplasms;
Infusion port;
Occlusion;
Risk assessment;
Scale;
Reliability and validity
- From:
Chinese Journal of Modern Nursing
2024;30(34):4709-4714
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To develop a risk assessment scale for infusion port occlusion in patients with malignant tumors and to test its reliability and validity.Methods:An initial item pool was constructed based on literature review. Through purposive sampling, two rounds of Delphi consultations with 20 experts were conducted from March to May 2023. Weights were assigned to the indicators using the analytic hierarchy process (AHP), and the risk assessment scale was finalized. From June to September 2023, a convenience sample of 278 malignant tumor patients with infusion ports from four Class Ⅲ Grade A hospitals in Shanxi Province was selected for item analysis and reliability and validity testing.Results:The risk assessment scale for infusion port occlusion in malignant tumor patients includes five dimensions, 16 primary indicators, and 35 secondary indicators. The content validity index at the scale level was 0.925, and at the item level ranged from 0.818 to 1.000. A total of five factors were extracted by exploratory factor analysis, with a cumulative contribution rate of 57.081% to the variance. The area under the receiver operating characteristic curve was 0.815, with a cutoff score of 24.50. The overall Cronbach's α coefficient was 0.910, and the split-half reliability coefficient was 0.762.Conclusions:The risk assessment scale for infusion port occlusion in malignant tumor patients demonstrates good reliability and validity, and has high predictive power, which provides a scientific basis for identifying high-risk populations in clinical settings.
